GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Net Issuance of Preferred Stock

Vericel (Vericel) Net Issuance of Preferred Stock : $0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Vericel Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Vericel's net issuance of preferred for the three months ended in Mar. 2024 was $0.0 Mil. The number is 0, which means that Vericel has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Vericel's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was $0.0 Mil.


Vericel Net Issuance of Preferred Stock Historical Data

The historical data trend for Vericel's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Net Issuance of Preferred Stock Chart

Vericel Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vericel Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vericel Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vericel Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Vericel's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Vericel (Vericel) Business Description

Industry
Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Executives
Dominick Colangelo director, officer: President and CEO 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md director
Paul K Wotton director C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn officer: SVP, General Counsel C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin officer: Chief Operating Officer C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal officer: Principal Accounting Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright director C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr officer: Chief Financial Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell officer: VP and Corporate Controller C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel officer: CFO & VP , Corp. Development 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando officer: Chief Operating Officer P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino director PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp 10 percent owner 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019

Vericel (Vericel) Headlines

From GuruFocus